New alliance for greater access to antiretrovirals in Brazil
Global HIV specialist ViiV Healthcare says that its majority owner, GlaxoSmithKline (LSE: GSK), has entered into a new partnership with the Institute of Technology in Pharmaceuticals (Farmanguinhos/Fiocruz) aiming to enable increased access to antiretroviral treatments in Brazil.
The agreement includes the transfer of technology and know-how for the local manufacture of dolutegravir 50mg, which was registered in Brazil by ViiV in 2014 and was introduced in the National Health System (SUS) in Brazil in 2016. GSK, ViiV’s distributor to Brazil, currently supplies sufficient dolutegravir to the Brazilian Ministry of Health, enabling about 300,000 Brazilian people living with HIV to access this treatment.
In the agreement, ViiV Healthcare will provide technical assistance for the development of lamivudine 300mg tablet, a drug that is already produced by Farmanguinhos in a 150mg dosage formulation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze